- Home
- SNCY vs SIGA Comparison
SNCY vs SIGA Comparison
Compare SNCY & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- SIGA
- Stock Information
- Founded
- SNCY 1982
- SIGA 1995
- Country
- SNCY United States
- SIGA United States
- Employees
- SNCY N/A
- SIGA N/A
- Industry
- SNCY Air Freight/Delivery Services
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- SNCY Consumer Discretionary
- SIGA Health Care
- Exchange
- SNCY Nasdaq
- SIGA Nasdaq
- Market Cap
- SNCY 549.7M
- SIGA 515.1M
- IPO Year
- SNCY 2021
- SIGA 1997
- Fundamental
- Price
- SNCY $13.81
- SIGA $8.84
- Analyst Decision
- SNCY Buy
- SIGA
- Analyst Count
- SNCY 7
- SIGA 0
- Target Price
- SNCY $17.00
- SIGA N/A
- AVG Volume (30 Days)
- SNCY 810.6K
- SIGA 511.7K
- Earning Date
- SNCY 10-29-2025
- SIGA 11-06-2025
- Dividend Yield
- SNCY N/A
- SIGA 6.88%
- EPS Growth
- SNCY 20.75
- SIGA N/A
- EPS
- SNCY 1.07
- SIGA 1.14
- Revenue
- SNCY $1,100,145,000.00
- SIGA $179,639,422.00
- Revenue This Year
- SNCY $6.16
- SIGA N/A
- Revenue Next Year
- SNCY $10.33
- SIGA $115.06
- P/E Ratio
- SNCY $12.77
- SIGA $7.65
- Revenue Growth
- SNCY 3.76
- SIGA 3.86
- 52 Week Low
- SNCY $8.10
- SIGA $4.95
- 52 Week High
- SNCY $18.59
- SIGA $9.62
- Technical
- Relative Strength Index (RSI)
- SNCY 63.97
- SIGA 58.71
- Support Level
- SNCY $12.45
- SIGA $8.49
- Resistance Level
- SNCY $13.41
- SIGA $9.09
- Average True Range (ATR)
- SNCY 0.54
- SIGA 0.32
- MACD
- SNCY 0.06
- SIGA -0.02
- Stochastic Oscillator
- SNCY 82.29
- SIGA 66.34
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.